By KIM BELLARD I recently read both Plastic, Inc. (Beth Gardiner) and These Are the Plunderers (Gretchen Morgenson and Joshua Rosner), and, boy, am I mad. Nothing in either book really came as a surprise, but the degree to which some people are willing to be greedy at the expense of others is still daunting….
CareValidate expanded its HRT offering for telehealth companies, combining hormone therapy with provider access, pharmacy services and AI-powered care coordination. The post CareValidate Launches Expanded HRT Offering appeared first on MedCity News.
Lycia Therapeutics’ protein-degrading drugs are based on the research of Carolyn Bertozzi, a Stanford chemistry professor and Nobel laureate. Lycia’s lead drug candidate is in development for food allergy, where it could compete against the blockbuster Roche drug Xolair. The post Lycia Lands a $317M IPO for Inflammation Drugs Based on Nobel Prize-Winning Science appeared…
The MATCH IT Act aims to reduce patient matching errors. But a model used by vital records systems could provide a better solution. The post Congress’s Patient Matching Fix Won’t Work — Here’s What Would appeared first on MedCity News.
In most organizations the default access model was built for patient care, not for protecting colleagues. A nurse on another unit, a resident who rotated with them, a department administrator: any of them may technically be able to open the record, even when policy says they should not. The post Physician Mental Health and Health…
Fractyl Health reported positive six-month trial results from an investigation of its Revita procedure last week, but shares of Fractyl stock dropped steeply on October 16 immediately following the announcement. Despite the positive findings, the stock’s sharp decline highlighted a contrast between the clinical findings and the market’s response. The post Fractyl’s Weight Maintenance Device…
New guide is written by and for patients
MedTech Conference panelists cited inflammation research, listening to women, clinical trial representation and investment as priorities for women’s cardiovascular health. The post Where Are the Biggest Opportunities in Women’s Cardiovascular Health? appeared first on MedCity News.
This analysis examines the $500 checks that the Trump administration is sending to some Affordable Care Act Marketplace enrollees and the user fees that are paying for them. The checks are going to about 1 million enrollees in the 30 states that rely on the federal HealthCare.gov Marketplace who are not receiving any tax credits…
Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 receptor to treat inflammatory bowel disease. It could compete against Johnson & Johnson’s Icotyde, an oral peptide that blocks the same target and is also in development for IBD. The post Gilead to Pay $1.3B for Oral…